Neuroendocrine responses to levodopa in multiple system atrophy (MSA)

Area of Science:

• Neuroendocrinology
• Neuroscience
• Clinical Neurology

Background:

• Hypothalamic dopaminergic pathways regulate pituitary hormone release, including growth hormone (GH) and prolactin.
• Multiple System Atrophy (MSA) is characterized by a reported loss of hypothalamic dopamine, but neuroendocrine studies are limited and conflicting.
• Understanding dopaminergic function in MSA is crucial for elucidating neuroendocrine disturbances.

Purpose of the Study:

• To investigate the neuroendocrine responses to levodopa in patients with MSA.
• To compare the effects of levodopa on GH, prolactin, and related hormones in MSA patients versus healthy controls.
• To determine if dopaminergic dysfunction in MSA is selective or generalized.

Main Methods:

• A neuroendocrine study involving the administration of levodopa (250 mg) plus carbidopa (25 mg).
• Participants included 15 subjects with MSA and 8 age- and sex-matched healthy control subjects.
• Measurements included basal and post-levodopa levels of GH, GHRH, glucose, IGF-1, TSH, and prolactin.

Main Results:

• No significant differences in basal or post-levodopa GH, GHRH, glucose, IGF-1, or TSH between MSA patients and controls.
• Basal prolactin levels were significantly elevated in MSA patients compared to controls.
• Levodopa administration showed increased variability and less suppression of prolactin in MSA patients, indicating impaired dopaminergic control.

Conclusions:

• The GHRH and GH responses to levodopa are preserved in MSA patients, similar to healthy controls.
• Dopaminergic suppression of prolactin secretion is impaired in MSA patients.
• This suggests a selective dysfunction of tubero-infundibular dopaminergic neurons in MSA, rather than a generalized loss.